SlideShare une entreprise Scribd logo
1  sur  23
Evaluation of  Acinetobacter  Infection Sarah Nelson, Pharm.D. Pharmacy Practice Resident
Acinetobacter ,[object Object],[object Object],[object Object],[object Object],Giamarellou, H. et al.  Acinetobacter baumannii:  a universal threat to public health?  International Journal of Antimicrobial Agents.2008;32:106-119
Clinical Manifestations ,[object Object],[object Object],[object Object],[object Object],[object Object],Giamarellou, H. et al.  Acinetobacter baumannii:  a universal threat to public health?  International Journal of Antimicrobial Agents.2008;32:106-119
Mechanisms of Resistance Munoz-Price, L. et al. Acinetobacter Infection.  N Engl J Med.  2008;358(12):1271-81
Current Treatment Options ,[object Object],[object Object],[object Object],[object Object]
Background ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter  baumannii infections.  J Antimicrob Chemother.  2008;61(2):417-420
Background Kwon, KT et al. Impact of imipenem resistance on mortality in patients with Acinetobacter  bacteremia.  J antimicrob Chemother . 2007;59:525-530 ,[object Object],[object Object],[object Object]
Objectives ,[object Object],[object Object],[object Object],[object Object]
Methods ,[object Object],[object Object],[object Object],[object Object]
Patients ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Data Collection ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Data Collection ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Statistical Analyses ,[object Object],[object Object],[object Object]
Study Subjects ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Demographics 22 (20%) >1 source of  Acinetobacter 2.6 2.5 2.5 Days to positive culture 32 27.5 28.5 LOS (days) 57.1 51.4 52.6 Age (years) 20 (59%) 38 (50%) 59 (53%) Male Unfavorable Outcome  (n= 34) Favorable Outcome  (n=76) Overall (n=112)
Source of Infection
Locality of Infection
Rates of Resistance 0% --- Colistin 31% --- Tigecycline 70% 48% Piperacillin/Tazobactam 64% 50% TMP/SMX 56% 31% Imipenem 68% 58% Gentamicin 76% 65% Ciprofloxacin 74% 60% Cefepime 72% --- Amikacin Study Group 2007 Antibiogram Antimicrobial
Empiric Therapy ,[object Object],[object Object],[object Object],[object Object],[object Object]
Tailored Antimicrobial Therapy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Colistin ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Limitations ,[object Object],[object Object],[object Object],[object Object]
Conclusion ,[object Object],[object Object],[object Object],[object Object]

Contenu connexe

Tendances

Gram Positive Cocci-Streptococcus
Gram Positive Cocci-StreptococcusGram Positive Cocci-Streptococcus
Gram Positive Cocci-StreptococcusDr. Samira Fattah
 
Streptococcus pneumoniae
Streptococcus pneumoniaeStreptococcus pneumoniae
Streptococcus pneumoniaeMANISH TIWARI
 
MRSA (Methicillin resistant staphylococcus aureus)
MRSA (Methicillin resistant staphylococcus aureus)MRSA (Methicillin resistant staphylococcus aureus)
MRSA (Methicillin resistant staphylococcus aureus)Nagaraj Salapakshi
 
Mycology - all about fungi
Mycology - all about fungiMycology - all about fungi
Mycology - all about fungiAshish Jawarkar
 
Immunity to Microbes
Immunity to MicrobesImmunity to Microbes
Immunity to MicrobesMd Murad Khan
 
Quality control of antimicrobial susceptibility tests
Quality control of antimicrobial susceptibility testsQuality control of antimicrobial susceptibility tests
Quality control of antimicrobial susceptibility testsAmr Eldakroury
 
Francisella tularensis
Francisella tularensisFrancisella tularensis
Francisella tularensisSamrasA
 
E coli, klebsiella, enterobacter lecture notes
E coli, klebsiella, enterobacter lecture notesE coli, klebsiella, enterobacter lecture notes
E coli, klebsiella, enterobacter lecture notesBruno Mmassy
 

Tendances (20)

Gram Positive Cocci-Streptococcus
Gram Positive Cocci-StreptococcusGram Positive Cocci-Streptococcus
Gram Positive Cocci-Streptococcus
 
Neisseria meningitidis
Neisseria meningitidisNeisseria meningitidis
Neisseria meningitidis
 
Anaerobic bacteria
Anaerobic bacteriaAnaerobic bacteria
Anaerobic bacteria
 
Rickettsiae
RickettsiaeRickettsiae
Rickettsiae
 
Neisseria final.pptx
Neisseria final.pptxNeisseria final.pptx
Neisseria final.pptx
 
Streptococcus pneumoniae
Streptococcus pneumoniaeStreptococcus pneumoniae
Streptococcus pneumoniae
 
MRSA (Methicillin resistant staphylococcus aureus)
MRSA (Methicillin resistant staphylococcus aureus)MRSA (Methicillin resistant staphylococcus aureus)
MRSA (Methicillin resistant staphylococcus aureus)
 
Rickettsia
RickettsiaRickettsia
Rickettsia
 
Mycology - all about fungi
Mycology - all about fungiMycology - all about fungi
Mycology - all about fungi
 
Campylobacter & Helicobacter
Campylobacter & HelicobacterCampylobacter & Helicobacter
Campylobacter & Helicobacter
 
Neisseria by Dr. Rakesh Prasad Sah
Neisseria by Dr. Rakesh Prasad SahNeisseria by Dr. Rakesh Prasad Sah
Neisseria by Dr. Rakesh Prasad Sah
 
Chlamydia
ChlamydiaChlamydia
Chlamydia
 
Immunity to Microbes
Immunity to MicrobesImmunity to Microbes
Immunity to Microbes
 
Actinomyces + nocardia
Actinomyces + nocardiaActinomyces + nocardia
Actinomyces + nocardia
 
Brucellosis dx.pptx
Brucellosis dx.pptxBrucellosis dx.pptx
Brucellosis dx.pptx
 
Quality control of antimicrobial susceptibility tests
Quality control of antimicrobial susceptibility testsQuality control of antimicrobial susceptibility tests
Quality control of antimicrobial susceptibility tests
 
Amp C (1).pptx
Amp C (1).pptxAmp C (1).pptx
Amp C (1).pptx
 
Francisella tularensis
Francisella tularensisFrancisella tularensis
Francisella tularensis
 
Microb e.coli
Microb e.coliMicrob e.coli
Microb e.coli
 
E coli, klebsiella, enterobacter lecture notes
E coli, klebsiella, enterobacter lecture notesE coli, klebsiella, enterobacter lecture notes
E coli, klebsiella, enterobacter lecture notes
 

En vedette

Acinetobacter: Awakening of a sleeping demon
Acinetobacter: Awakening of a sleeping demonAcinetobacter: Awakening of a sleeping demon
Acinetobacter: Awakening of a sleeping demonShyam Mishra
 
Acinetobacter
AcinetobacterAcinetobacter
Acinetobacterraza3182
 
Antibiotic susceptibility of multidrug-resistant nosocomial bacteria Acinetob...
Antibiotic susceptibility of multidrug-resistant nosocomial bacteria Acinetob...Antibiotic susceptibility of multidrug-resistant nosocomial bacteria Acinetob...
Antibiotic susceptibility of multidrug-resistant nosocomial bacteria Acinetob...Enid Cruz
 
Mtalib baumannii acinetobacter 2
Mtalib   baumannii acinetobacter 2Mtalib   baumannii acinetobacter 2
Mtalib baumannii acinetobacter 2kl jkl
 
Colistin - Old Antibiotic for New MDR Pathogens
Colistin - Old Antibiotic for New MDR PathogensColistin - Old Antibiotic for New MDR Pathogens
Colistin - Old Antibiotic for New MDR PathogensMohamad Abdelsalam
 
Journal Reading: Colistin IV+IH vs. iv Alone for VAP
Journal Reading: Colistin IV+IH vs. iv Alone for VAPJournal Reading: Colistin IV+IH vs. iv Alone for VAP
Journal Reading: Colistin IV+IH vs. iv Alone for VAPVictoria Jian
 
Evaluation of the changes in the gene CYP3A4 expression in HepG2 cells under ...
Evaluation of the changes in the gene CYP3A4 expression in HepG2 cells under ...Evaluation of the changes in the gene CYP3A4 expression in HepG2 cells under ...
Evaluation of the changes in the gene CYP3A4 expression in HepG2 cells under ...Angela Farngren
 
Drugs and The Liver
Drugs and The Liver Drugs and The Liver
Drugs and The Liver Dr Htet
 
이연석 EPI Presentation
이연석 EPI Presentation이연석 EPI Presentation
이연석 EPI PresentationAustin Lee
 
Week 4- the two open compartment
Week 4- the two open compartmentWeek 4- the two open compartment
Week 4- the two open compartmentlichlmh
 
Rifampicin aki vasif
Rifampicin aki vasifRifampicin aki vasif
Rifampicin aki vasifVasif Mayan
 
ACT antimicrobial susceptibility testing, inoculation and drug sensitivity
ACT antimicrobial susceptibility testing, inoculation and drug sensitivity ACT antimicrobial susceptibility testing, inoculation and drug sensitivity
ACT antimicrobial susceptibility testing, inoculation and drug sensitivity Arsh Gull
 
dry powder aerosols
dry powder aerosolsdry powder aerosols
dry powder aerosolsBHARGAV
 

En vedette (20)

Acinetobacter: Awakening of a sleeping demon
Acinetobacter: Awakening of a sleeping demonAcinetobacter: Awakening of a sleeping demon
Acinetobacter: Awakening of a sleeping demon
 
Acinetobacter
AcinetobacterAcinetobacter
Acinetobacter
 
Acinetobacter
Acinetobacter Acinetobacter
Acinetobacter
 
Antibiotic susceptibility of multidrug-resistant nosocomial bacteria Acinetob...
Antibiotic susceptibility of multidrug-resistant nosocomial bacteria Acinetob...Antibiotic susceptibility of multidrug-resistant nosocomial bacteria Acinetob...
Antibiotic susceptibility of multidrug-resistant nosocomial bacteria Acinetob...
 
Acinetobacter
AcinetobacterAcinetobacter
Acinetobacter
 
Mtalib baumannii acinetobacter 2
Mtalib   baumannii acinetobacter 2Mtalib   baumannii acinetobacter 2
Mtalib baumannii acinetobacter 2
 
Colistin - Old Antibiotic for New MDR Pathogens
Colistin - Old Antibiotic for New MDR PathogensColistin - Old Antibiotic for New MDR Pathogens
Colistin - Old Antibiotic for New MDR Pathogens
 
Drug resistant gram - ve bacteria
Drug resistant gram -  ve bacteriaDrug resistant gram -  ve bacteria
Drug resistant gram - ve bacteria
 
Journal Reading: Colistin IV+IH vs. iv Alone for VAP
Journal Reading: Colistin IV+IH vs. iv Alone for VAPJournal Reading: Colistin IV+IH vs. iv Alone for VAP
Journal Reading: Colistin IV+IH vs. iv Alone for VAP
 
Evaluation of the changes in the gene CYP3A4 expression in HepG2 cells under ...
Evaluation of the changes in the gene CYP3A4 expression in HepG2 cells under ...Evaluation of the changes in the gene CYP3A4 expression in HepG2 cells under ...
Evaluation of the changes in the gene CYP3A4 expression in HepG2 cells under ...
 
Future Perfect
Future Perfect Future Perfect
Future Perfect
 
Drugs and The Liver
Drugs and The Liver Drugs and The Liver
Drugs and The Liver
 
이연석 EPI Presentation
이연석 EPI Presentation이연석 EPI Presentation
이연석 EPI Presentation
 
Week 4- the two open compartment
Week 4- the two open compartmentWeek 4- the two open compartment
Week 4- the two open compartment
 
Rifampicin aki vasif
Rifampicin aki vasifRifampicin aki vasif
Rifampicin aki vasif
 
Vaibhav tb
Vaibhav tbVaibhav tb
Vaibhav tb
 
ACT antimicrobial susceptibility testing, inoculation and drug sensitivity
ACT antimicrobial susceptibility testing, inoculation and drug sensitivity ACT antimicrobial susceptibility testing, inoculation and drug sensitivity
ACT antimicrobial susceptibility testing, inoculation and drug sensitivity
 
dry powder aerosols
dry powder aerosolsdry powder aerosols
dry powder aerosols
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
Ppt on tb
Ppt on tbPpt on tb
Ppt on tb
 

Similaire à Evaluation Of Acinetobacter Infection, Eastern States Presentation

UC journal club.pptx
UC journal club.pptxUC journal club.pptx
UC journal club.pptxKareemSayed17
 
Zyvac tcv the Indian typhoid conjugate vaccination - Yamunanagar aug 2018
Zyvac tcv the Indian typhoid conjugate vaccination - Yamunanagar aug 2018Zyvac tcv the Indian typhoid conjugate vaccination - Yamunanagar aug 2018
Zyvac tcv the Indian typhoid conjugate vaccination - Yamunanagar aug 2018Gaurav Gupta
 
¿Tiene utilidad el probiótico en la prevención de infecciones en el ámbito ho...
¿Tiene utilidad el probiótico en la prevención de infecciones en el ámbito ho...¿Tiene utilidad el probiótico en la prevención de infecciones en el ámbito ho...
¿Tiene utilidad el probiótico en la prevención de infecciones en el ámbito ho...Societat Catalana de Farmàcia Clínica
 
K.S. Filos, MD PhD Selective Gut Decontamination
K.S. Filos, MD PhD   Selective Gut DecontaminationK.S. Filos, MD PhD   Selective Gut Decontamination
K.S. Filos, MD PhD Selective Gut DecontaminationKriton Filos
 
Utility of routine surveillance blood cultures in asymptomatic allogeneic he...
 Utility of routine surveillance blood cultures in asymptomatic allogeneic he... Utility of routine surveillance blood cultures in asymptomatic allogeneic he...
Utility of routine surveillance blood cultures in asymptomatic allogeneic he...Ahmed Abdelhakeem
 
Combination antibiotic therapy bacteremic pneumococcal pneumonia: PRO
Combination antibiotic therapy bacteremic pneumococcal pneumonia: PROCombination antibiotic therapy bacteremic pneumococcal pneumonia: PRO
Combination antibiotic therapy bacteremic pneumococcal pneumonia: PROIdibaps Respiratory Research Group
 
Presentación Hospital Dr. Negrín Paris 2013
Presentación Hospital Dr. Negrín Paris 2013Presentación Hospital Dr. Negrín Paris 2013
Presentación Hospital Dr. Negrín Paris 2013Fanoestudio.com
 
Современное лечение ВИЧ: лечение многократно леченных пациентов с резистентно...
Современное лечение ВИЧ: лечение многократно леченных пациентов с резистентно...Современное лечение ВИЧ: лечение многократно леченных пациентов с резистентно...
Современное лечение ВИЧ: лечение многократно леченных пациентов с резистентно...hivlifeinfo
 
Antibiotic prophylaxis in sever Acute Panceriatitis
Antibiotic prophylaxis in sever Acute PanceriatitisAntibiotic prophylaxis in sever Acute Panceriatitis
Antibiotic prophylaxis in sever Acute PanceriatitisSaeed Al-Shomimi
 
Journal club presentation: by RxVichuZ!! ;)
Journal club presentation: by RxVichuZ!! ;)Journal club presentation: by RxVichuZ!! ;)
Journal club presentation: by RxVichuZ!! ;)RxVichuZ
 
Invasive candidiasis the hidden cause of sepsis
Invasive candidiasis the hidden cause of sepsisInvasive candidiasis the hidden cause of sepsis
Invasive candidiasis the hidden cause of sepsisKhaled Taema
 
You can’t treat pancreatitis without antibiotics by Dr Emma Goeman
You can’t treat pancreatitis without antibiotics by Dr Emma GoemanYou can’t treat pancreatitis without antibiotics by Dr Emma Goeman
You can’t treat pancreatitis without antibiotics by Dr Emma GoemanSMACC Conference
 
Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarr...
Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarr...Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarr...
Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarr...Utai Sukviwatsirikul
 
Probioticos x antibóticos
Probioticos x antibóticosProbioticos x antibóticos
Probioticos x antibóticoslactivos
 
Latest Developments in Intravesical Therapy
Latest Developments in Intravesical Therapy Latest Developments in Intravesical Therapy
Latest Developments in Intravesical Therapy BJUI
 
H A P& V A P
H A P& V A PH A P& V A P
H A P& V A PMed Bee
 
ANTIMICROBIAL RESISTANCE PATTERNS AMONG ACINETOBACTER BAUMANNII ISOLATED FROM...
ANTIMICROBIAL RESISTANCE PATTERNS AMONG ACINETOBACTER BAUMANNII ISOLATED FROM...ANTIMICROBIAL RESISTANCE PATTERNS AMONG ACINETOBACTER BAUMANNII ISOLATED FROM...
ANTIMICROBIAL RESISTANCE PATTERNS AMONG ACINETOBACTER BAUMANNII ISOLATED FROM...inventionjournals
 
ANTIMICROBIAL RESISTANCE PATTERNS AMONG ACINETOBACTER BAUMANNII ISOLATED FROM...
ANTIMICROBIAL RESISTANCE PATTERNS AMONG ACINETOBACTER BAUMANNII ISOLATED FROM...ANTIMICROBIAL RESISTANCE PATTERNS AMONG ACINETOBACTER BAUMANNII ISOLATED FROM...
ANTIMICROBIAL RESISTANCE PATTERNS AMONG ACINETOBACTER BAUMANNII ISOLATED FROM...inventionjournals
 

Similaire à Evaluation Of Acinetobacter Infection, Eastern States Presentation (20)

UC journal club.pptx
UC journal club.pptxUC journal club.pptx
UC journal club.pptx
 
Zyvac tcv the Indian typhoid conjugate vaccination - Yamunanagar aug 2018
Zyvac tcv the Indian typhoid conjugate vaccination - Yamunanagar aug 2018Zyvac tcv the Indian typhoid conjugate vaccination - Yamunanagar aug 2018
Zyvac tcv the Indian typhoid conjugate vaccination - Yamunanagar aug 2018
 
¿Tiene utilidad el probiótico en la prevención de infecciones en el ámbito ho...
¿Tiene utilidad el probiótico en la prevención de infecciones en el ámbito ho...¿Tiene utilidad el probiótico en la prevención de infecciones en el ámbito ho...
¿Tiene utilidad el probiótico en la prevención de infecciones en el ámbito ho...
 
Int j healthalliedsci_2016_5_4_210_194083
Int j healthalliedsci_2016_5_4_210_194083Int j healthalliedsci_2016_5_4_210_194083
Int j healthalliedsci_2016_5_4_210_194083
 
K.S. Filos, MD PhD Selective Gut Decontamination
K.S. Filos, MD PhD   Selective Gut DecontaminationK.S. Filos, MD PhD   Selective Gut Decontamination
K.S. Filos, MD PhD Selective Gut Decontamination
 
Utility of routine surveillance blood cultures in asymptomatic allogeneic he...
 Utility of routine surveillance blood cultures in asymptomatic allogeneic he... Utility of routine surveillance blood cultures in asymptomatic allogeneic he...
Utility of routine surveillance blood cultures in asymptomatic allogeneic he...
 
Combination antibiotic therapy bacteremic pneumococcal pneumonia: PRO
Combination antibiotic therapy bacteremic pneumococcal pneumonia: PROCombination antibiotic therapy bacteremic pneumococcal pneumonia: PRO
Combination antibiotic therapy bacteremic pneumococcal pneumonia: PRO
 
Salzer
SalzerSalzer
Salzer
 
Presentación Hospital Dr. Negrín Paris 2013
Presentación Hospital Dr. Negrín Paris 2013Presentación Hospital Dr. Negrín Paris 2013
Presentación Hospital Dr. Negrín Paris 2013
 
Современное лечение ВИЧ: лечение многократно леченных пациентов с резистентно...
Современное лечение ВИЧ: лечение многократно леченных пациентов с резистентно...Современное лечение ВИЧ: лечение многократно леченных пациентов с резистентно...
Современное лечение ВИЧ: лечение многократно леченных пациентов с резистентно...
 
Antibiotic prophylaxis in sever Acute Panceriatitis
Antibiotic prophylaxis in sever Acute PanceriatitisAntibiotic prophylaxis in sever Acute Panceriatitis
Antibiotic prophylaxis in sever Acute Panceriatitis
 
Journal club presentation: by RxVichuZ!! ;)
Journal club presentation: by RxVichuZ!! ;)Journal club presentation: by RxVichuZ!! ;)
Journal club presentation: by RxVichuZ!! ;)
 
Invasive candidiasis the hidden cause of sepsis
Invasive candidiasis the hidden cause of sepsisInvasive candidiasis the hidden cause of sepsis
Invasive candidiasis the hidden cause of sepsis
 
You can’t treat pancreatitis without antibiotics by Dr Emma Goeman
You can’t treat pancreatitis without antibiotics by Dr Emma GoemanYou can’t treat pancreatitis without antibiotics by Dr Emma Goeman
You can’t treat pancreatitis without antibiotics by Dr Emma Goeman
 
Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarr...
Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarr...Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarr...
Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarr...
 
Probioticos x antibóticos
Probioticos x antibóticosProbioticos x antibóticos
Probioticos x antibóticos
 
Latest Developments in Intravesical Therapy
Latest Developments in Intravesical Therapy Latest Developments in Intravesical Therapy
Latest Developments in Intravesical Therapy
 
H A P& V A P
H A P& V A PH A P& V A P
H A P& V A P
 
ANTIMICROBIAL RESISTANCE PATTERNS AMONG ACINETOBACTER BAUMANNII ISOLATED FROM...
ANTIMICROBIAL RESISTANCE PATTERNS AMONG ACINETOBACTER BAUMANNII ISOLATED FROM...ANTIMICROBIAL RESISTANCE PATTERNS AMONG ACINETOBACTER BAUMANNII ISOLATED FROM...
ANTIMICROBIAL RESISTANCE PATTERNS AMONG ACINETOBACTER BAUMANNII ISOLATED FROM...
 
ANTIMICROBIAL RESISTANCE PATTERNS AMONG ACINETOBACTER BAUMANNII ISOLATED FROM...
ANTIMICROBIAL RESISTANCE PATTERNS AMONG ACINETOBACTER BAUMANNII ISOLATED FROM...ANTIMICROBIAL RESISTANCE PATTERNS AMONG ACINETOBACTER BAUMANNII ISOLATED FROM...
ANTIMICROBIAL RESISTANCE PATTERNS AMONG ACINETOBACTER BAUMANNII ISOLATED FROM...
 

Evaluation Of Acinetobacter Infection, Eastern States Presentation

  • 1. Evaluation of Acinetobacter Infection Sarah Nelson, Pharm.D. Pharmacy Practice Resident
  • 2.
  • 3.
  • 4. Mechanisms of Resistance Munoz-Price, L. et al. Acinetobacter Infection. N Engl J Med. 2008;358(12):1271-81
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15. Demographics 22 (20%) >1 source of Acinetobacter 2.6 2.5 2.5 Days to positive culture 32 27.5 28.5 LOS (days) 57.1 51.4 52.6 Age (years) 20 (59%) 38 (50%) 59 (53%) Male Unfavorable Outcome (n= 34) Favorable Outcome (n=76) Overall (n=112)
  • 18. Rates of Resistance 0% --- Colistin 31% --- Tigecycline 70% 48% Piperacillin/Tazobactam 64% 50% TMP/SMX 56% 31% Imipenem 68% 58% Gentamicin 76% 65% Ciprofloxacin 74% 60% Cefepime 72% --- Amikacin Study Group 2007 Antibiogram Antimicrobial
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.

Notes de l'éditeur

  1. Talk about genus and species, acinetobacter calcoaceticus and baumannii
  2. β -lactamase & ESBL production β -lactams, cephalosporins, carbapenems Alteration in porin structure carbapenems Overexpression of efflux pumps β -lactams, quinolones, tetracyclines, chloramphenicol, tigecycline, aminoglycosides, trimethoprim
  3. Rationale: Infections with Acinetobacter have become problematic at MCVH MDR Acinetobacter infections have resulted in: Prolonged exposure to ineffective antibiotics Increased length of treatment and hospital stay Increased occurrence of adverse reactions, including renal failure
  4. Antimicrobial Drug Therapy: Antimicrobial Therapy Drug Dose Duration Dosage formulation Alteration due to C&S results Monotherapy vs. Combination Therapy Presence of Adverse Effects SCr ( ≥2x baseline) and/or BUN ( ≥2x baseline) within 1 week of initiation of therapy